IPP Bureau

FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich
FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich

By IPP Bureau - December 02, 2025

This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA

Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers
Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers

By IPP Bureau - December 02, 2025

Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM

Lilly slashes prices on Zepbound vials to expanding access to obesity treatment
Lilly slashes prices on Zepbound vials to expanding access to obesity treatment

By IPP Bureau - December 02, 2025

Patients can now get the starting 2.5 mg dose for $299 per month

Bayer welcomes US Solicitor General’s support as Supreme Court weighs Roundup case
Bayer welcomes US Solicitor General’s support as Supreme Court weighs Roundup case

By IPP Bureau - December 02, 2025

At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits

Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis
Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis

By IPP Bureau - December 01, 2025

Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials

Lupin receives FDA approval for biosimilar Armlupeg
Lupin receives FDA approval for biosimilar Armlupeg

By IPP Bureau - December 01, 2025

Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs

Roche expands Veeva partnership with global rollout of AI-driven Vault CRM
Roche expands Veeva partnership with global rollout of AI-driven Vault CRM

By IPP Bureau - December 01, 2025

Roche says the move marks a step forward in its digital transformation strategy

OSR Holdings moves towards major licensing deal for oral cancer immunotherapy
OSR Holdings moves towards major licensing deal for oral cancer immunotherapy

By IPP Bureau - December 01, 2025

Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones

LANXESS unveils next-gen biosecurity solutions for Indian poultry market at Poultry Expo
LANXESS unveils next-gen biosecurity solutions for Indian poultry market at Poultry Expo

By IPP Bureau - December 01, 2025

LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments

Sudapack breaks ground on major PharmaGuard expansion in Erolzheim
Sudapack breaks ground on major PharmaGuard expansion in Erolzheim

By IPP Bureau - December 01, 2025

Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production

Global measles deaths plunge but cases surge, says WHO
Global measles deaths plunge but cases surge, says WHO

By IPP Bureau - December 01, 2025

In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic

SciSparc acquires Xylo Technologies' innovative endoscopic portfolio
SciSparc acquires Xylo Technologies' innovative endoscopic portfolio

By IPP Bureau - December 01, 2025

The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate
SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate

By IPP Bureau - December 01, 2025

Feinstein Institutes awarded $3.37 million grant to boost first responder mental health
Feinstein Institutes awarded $3.37 million grant to boost first responder mental health

By IPP Bureau - December 01, 2025

The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas

Lung Cancer Canada and Boehringer Ingelheim team up to transform lung cancer detection
Lung Cancer Canada and Boehringer Ingelheim team up to transform lung cancer detection

By IPP Bureau - December 01, 2025

Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes

Latest Stories

Interviews

Packaging